|
Feb 1
|
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call Transcript
|
|
Feb 1
|
Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates
|
|
Jan 31
|
Dr. Reddy’s Q3 & 9M FY24 Financial Results
|
|
Dec 6
|
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
|
|
Nov 2
|
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
|